Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1b symbols : LIFE save search
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.64 1.23% 66K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
biopharma phase 1 positive trial phase 1b phase 2b
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.64 1.23% 66K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Published: 2021-07-08 (Crawled : 14:15) - biospace.com/
LIFE | $1.64 1.23% 66K
|
Health Technology
|
| O: -1.75%
H: 4.91%
C: 4.46%
phase 1 trial phase 1b phase 2b
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
LIFE | $1.64 1.23% 66K
|
Health Technology
|
| O: 0.74%
H: 8.56%
C: 3.91%
trial phase 1b phase 2b enroll pharma
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.93 64.96% 55M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
RCAT | $1.52 26.67% 1.3M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.